ArticleCurrent neuropharmacology2013
Resolvins: Endogenously-Generated Potent Painkilling Substances and their Therapeutic Perspectives.
Article in Current neuropharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Trial
- Resolvin D1 requires TLR2-FPR2 crosstalk for inflammation resolution and protection during ocular bacterial infection.Communications biology · 2026Article
- GnRH peripherally modulates nociceptor functions, exacerbating mechanical pain.Frontiers in molecular neuroscience · 2024Article
- Transgenic mice overexpressing human ALOX15 under the control of the aP2 promoter are partly protected in the complete Freund's adjuvant-induced paw inflammation model.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Humanization of the Reaction Specificity of Mouse Alox15b Inversely Modified the Susceptibility of Corresponding Knock-In Mice in Two Different Animal Inflammation Models.International journal of molecular sciences · 2023Article
- Intranasal Administration of Resolvin E1 Produces Antidepressant-Like Effects via BDNF/VEGF-mTORC1 Signaling in the Medial Prefrontal Cortex.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023Article
- Resolvin E1 is a pro-repair molecule that promotes intestinal epithelial wound healing.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- The Perspective of Diagnostic and Prognostic Values of Lipoxygenases mRNA Expression in Colon Adenocarcinoma.OncoTargets and therapy · 2020Article
- Pathological mechanisms and therapeutic outlooks for arthrofibrosis.Bone research · 2019Article
- Resolvin D2 Relieving Radicular Pain is Associated with Regulation of Inflammatory Mediators, Akt/GSK-3β Signal Pathway and GPR18.Neurochemical research · 2018Article
- Schistosomal Lipids Activate Human Eosinophils via Toll-Like Receptor 2 and PGDFrontiers in immunology · 2018Article
- Association of the resolvin precursor 17-HDHA, but not D- or E- series resolvins, with heat pain sensitivity and osteoarthritis pain in humans.Scientific reports · 2017Article
- Targeting the D Series Resolvin Receptor System for the Treatment of Osteoarthritis Pain.Arthritis & rheumatology (Hoboken, N.J.) · 2017Article
- Modulation of the Activities of Neuronal Ion Channels by Fatty Acid-Derived Pro-Resolvents.Frontiers in physiology · 2016Review
- Emerging Role of Spinal Cord TRPV1 in Pain Exacerbation.Neural plasticity · 2016Review
- Review
- Mammalian lipoxygenases and their biological relevance.Biochimica et biophysica acta · 2015Review
- Biological Roles of Resolvins and Related Substances in the Resolution of Pain.BioMed research international · 2015Review
- Sensory TRP channel interactions with endogenous lipids and their biological outcomes.Molecules (Basel, Switzerland) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy of many of pain-relieving drugs is based on mechanisms by which the drugs interfere with the body's natural pain-mediating pathways. By contrast, although it is less popular, other drugs including opioids exert more powerful analgesic actions by augmenting endogenous inhibitory neural circuits for pain mediation. Recently, a novel endogenous pain-inhibitory principle was suggested and is now attracting both scientific and clinical attentions. The central players for the actions are particular body lipids: resolvins. Although research is in the preclinical phase, multiple hypotheses have actively been matured regarding the potency and molecular and neural processes of the analgesic effects of these substances. Consistently, accumulating experimental evidence has been demonstrating that treatment with these lipid substances is strongly effective at controlling diverse types of pain. Treatment of resolvins does not appear to disturb the body homeostasis as severely as many other therapeutic agents that interrupt the body's natural signaling flow, which enables us to predict their fewer adverse effects. This paper serves as a review of currently documented painkilling actions of resolvins, summarizes the potential cellular and receptor-mediated mechanisms to date, and discusses the many clinical uses for these therapeutic lipids that have not yet been tested. Future scientific efforts will more concentrate to unveil such aspects of the substances and to construct clear proofs of concept for pain relief.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.